Home > Insider Trading > Filing (0001209191-15-044684)

Filing Details

Accession Number:: 0001209191-15-044684
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-05-19 20:01:02
Reporting Period:: 2015-05-15

Filing Date:: 2015-05-19
Accepted Time:: 2015-05-19 20:01:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1510580	Kite Pharma Inc.	KITE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1610823	Jeffrey Wiezorek	C/O Kite Pharma, Inc. 2225 Colorado Avenue Santa Monica CA 90404	Vp Clinical Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-05-15	9,000	$6.89	10,218	No	4	M	Direct
Common Stock	Disposition	2015-05-15	4,706	$49.44	5,512	No	4	S	Direct
Common Stock	Disposition	2015-05-15	2,638	$50.49	2,874	No	4	S	Direct
Common Stock	Disposition	2015-05-15	1,528	$51.57	1,346	No	4	S	Direct
Common Stock	Disposition	2015-05-15	128	$52.21	1,218	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Disposition	2015-05-15	9,000	$0.00	9,000	$6.89

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
166,000		2024-06-05	No	4	M	Direct

Footnotes

Includes 1,218 shares acquired under the 2014 Employee Stock Purchase Plan on February 20, 2015.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2015.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $49.05 to $50.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $50.06 to $51.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.07 to $51.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.12 to $52.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
25% of the 175,000 shares subject to the stock option vested and became exercisable on May 5, 2015, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.